According to data from Pattern®, the leading e-commerce brand accelerator, CeraVe has defended its first spot every quarter since early 2023 as the top selling brand on Amazon, but its grip has been loosening. The brand’s share has contracted from 4.45% to 3.85% over three years. Meanwhile, La Roche-Posay has climbed from 2.68% to 3.26%, compressing the gap to just 59 basis points.
The most significant structural changes, however, are happening further down the ranking. Neutrogena, once a solid number two with 3.44%, has lost 128 basis points of share and now sits fourth. This erosion signals a consumer pivot away from mass-market heritage names toward targeted clinical positioning.
Enter Medicube. The Korean beauty label did not register in the top ten during 2023 or 2024 but by the fourth quarter of 2025, it claimed 2.35% of the category, having nearly doubled its share in the twelve months since its debut. Medicube’s parent company APR reported overseas revenue up 203% year-on-year in Q4, with the brand accounting for roughly $1.1 billion of the group’s $1.2 billion annual turnover.
Medicube’s growth engine rests on two pillar: problem-specific formulations such as the Zero Pore Pads, and a hardware bridge via the Age-R Booster Pro device. By pairing topical treatments with at-home tech, the brand solved the efficacy equation that creams alone cannot.
Distribution strategy mattered equally. Medicube treated TikTok not only as a communication platform but as a sales channel and validation loop. It amassed nearly 34,000 affiliate creators, turning micro-influencers into a distributed explainer force. When Kylie Jenner posted about the Booster Pro last April, the brand already had the infrastructure to convert attention into units. During Prime Day alone, that translated into $22 million.
The company then moved from virality to permanence, securing placement in 1,400 Ulta stores by late 2025. That digital velocity married to physical distribution explains how a brand absent from the top ten just a year ago now sits alongside CeraVe and La Roche-Posay.